Aptahem adjusts the schedule and capital requirements as a result of the decision to update the clinical development strategy
2017-04-03
Aptahem’s preclinical programme is proceeding with the gradual collection of data on the Apta-1 effect profile, while the work on the company’s clinical development is proceeding in consultation with external experts. Dialogue with opinion leaders and potential partners has...
Read More